THC Therapeutics is a development-stage company with no revenue, no customers, and one full-time employee. Its core focus is developing and commercializing the dHydronator®, a patented device designed to dry and sanitize freshly harvested cannabis and other herbs. The device uses UV light to reduce bacterial counts and can lower cannabis moisture content to 10-15% in 10-14 hours, compared to up to two weeks using traditional drying methods. THC Therapeutics holds a granted U.S. patent on the device and has a functioning prototype, but has not begun manufacturing or sales. The intended business model is to sell the dHydronator® to commercial cannabis growers and herb producers, with a potential secondary revenue stream from licensing its IP. The company estimates it needs at least $2M in cash before it can begin tooling, pre-production manufacturing, marketing, and hiring. In June 2025, THC Therapeutics acquired The Headquarters Group, an Oregon corporation, though the nature of that business has not been disclosed. The company has a history of repeated pivots since its 2007 incorporation in Nevada, having operated under several names and business focuses including children's party products, oil and gas, and blockchain before returning to its current cannabis-focused strategy.